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Abstract 
Functional GI disorders are categorized as a group of chronic symptoms that are considered to have no 
abnormalities that can account for patient’s illnesses. Included in this category are those patients with 
irritable bowel syndrome. Functional GI issues are an important public health concern as they are 
becoming increasingly more common; they can be disabling and can cause significant socioeconomic 
burden in regard to health care costs, productivity and disability. There is strong evidence that probiotics 
have the potential to reduce IBS symptoms. Unfortunately, probiotics are underutilized in the clinical 
setting. 
The purpose of this project is to increase knowledge and self-efficacy in patients with functional 
GI symptoms regarding the use of probiotics for symptom management. Patients in an outpatient GI 
practice in Southwestern United States with chronic functional GI symptoms were shown an educational 
video regarding the origins and benefits of using probiotics to manage chronic symptoms.  Knowledge of 
probiotics, self-efficacy and willingness to utilize probiotics was measured by asking participants to 
complete a modified Health Belief Model survey before and after viewing the video.  Patient 
demographics were collected.  There were 75 participants (n=75) who participated in the project with a 
mean age of 40.3 years (SD=15.41), 85% female and 15% male. Wilcoxon signed rank test were used to 
analyze changes in paired data with significant improvements in self-efficacy (Z=3.93, p< .01), benefits 
of probiotic use (Z=4.33, p<.01) and decreased barriers to probiotics use (Z=-4.31, p<.01). After 
participants viewed the educational video, 95% of patients indicated they would try probiotics (CI 95%, 
p<.01) versus 65% of patients who would try probiotics before viewing video. In conclusion, education 
regarding using probiotics to manage functional GI symptoms improved patient’s self-efficacy and their 
willingness to use probiotics to manage their symptoms. Keywords: probiotics, GI disorders, diarrhea, 
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Education and Self-efficacy of Probiotic Use in Patients with Chronic Gastrointestinal Symptoms 
Functional gastrointestinal (GI) disorders are categorized as a group of chronic symptoms 
that are considered to have no structural or biochemical abnormalities that can account for patient’s 
illness. Included in this category are those patients diagnosed with irritable bowel syndrome (IBS). 
IBS is chronic GI disorder characterized by abdominal pain accompanied by altered bowel 
function, gas and bloating without the presence of organic disease (Mapel, 2013). Functional 
gastrointestinal symptoms typically include complaints of long-standing issues (greater than 3 
months) of diarrhea, abdominal pain, constipation, gas and bloating.  
Background and Significance 
Functional GI issues have become an important public health concern for a number of 
reasons: they are becoming increasingly more common; they can be disabling and can cause 
significant socioeconomic burden in regard to health care costs, productivity and disability (Mapel, 
2013). According to the National Institute of Health, chronic gastrointestinal symptoms account for 
over $40 billion/year in health care in direct and indirect costs in the United States (U.S. 
Department of Health and Human Services, 2012).These costs place IBS among the 10 most 
expensive GI diseases in the U.S. and is one of the most common reasons for visits to 
gastroenterologists and primary care physician offices (Ford et al., 2014). Approximately 3600 
patient are seen per year in an outpatient gastroenterology clinic located in Southwestern United 
States, 67%  (2142) of the patients  had diagnosis codes that included some combination of 
abdominal pain, gas, bloating, IBS and constipation and were seen at least once a month for a 6 
month period for these symptoms. On average each office visit was approximately 20 minutes to 
45 minutes in length with a mean average of 30 minutes/office visit. At an average collected cost 
of $65.00/office visit, approximately $390.00 was spent on each patient in a 6 month time period 
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for a total collected cost of $1,670,760.00 in health care dollars spent on intractable GI symptoms 
per year at this clinic. Each office visit is allocated 15 minutes, however the mean time for an 
office visit for these patients was 30 minutes which affects provider time, patient satisfaction and 
increased staff workload. This internal data illustrates the financial burden, prevalence of the 
disease, and the need for further evaluation of potential effective therapies. 
      Purpose and Rationale 
 Recent interest in probiotics use has been generated from both patients and primary care 
providers in their use and efficacy in treating chronic gastrointestinal symptoms. Probiotics are 
defined by the World Health Organization (WHO) as “live microorganisms which when 
administered in adequate amounts confer a health benefit to the host” (World Health Organization, 
2002, p.1). The term probiotic was first used in the 1960’s, however the beneficial effects of foods 
containing live bacteria have been recognized for centuries (Emmanuel, 2013). Biologist Elie 
Metchnikoff was awarded the Nobel Prize in 1908 for his pioneering research into the relationship 
between immunity and bacteria (Emmanuel, 2013). His seminal work led to the concept of balance 
between beneficial and harmful bacteria in the gut.  
Probiotics, which are controlled by the U.S. Federal Drug Administration as dietary 
supplements, consist of yeast or bacteria and may contain a single microorganism or a combination 
of several species of bacteria (Hempel et al., 2012).  Although the exact mechanism of action of 
probiotics are not known, a general consensus model proposes that lactic acid bacteria species can 
lower the intestinal pH which controls the growth of pathogenic bacteria, thereby reestablishing the 
balance of gut microbial flora (Hempel et al., 2012). In addition, other proposed mechanisms of 
action include immunomodulation, production of pathogenic bacterial toxins and the obstruction of 
pathogen adhesion to intestinal epithelium cells lining the GI tract. (Ford et al., 2014).   
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As probiotics have grown in popularity, knowledge of the implications regarding probiotic 
effectiveness and the need for patient education regarding their use needs to be paramount for 
providers.  In addition, there have been conflicting media reports on probiotics which has led to 
increased confusion among patients as well as among health professionals as to the effectiveness 
of probiotics in treating GI symptoms. This inquiry has led to the clinically relevant PICOT 
Question: In adult patients seen in the outpatient setting, does the use of further education 
regarding probiotics increase patient’s willingness and self-efficacy to use probiotics in patients 
with chronic GI symptoms  (diarrhea, constipation, gas, bloating, IBS) ? 
         Search Strategy and Study Selection 
A thorough literature search of multiple data bases was performed. Studies were identified 
through searching electronic databases and scanning reference lists of relevant articles published 
within the past ten years. An electronic search of the published literature was conducted using 
PubMed, CINAHL, and the Cochrane Central Registry of Controlled Trials for relevant studies. 
The principal search word terms and MESH headings used alone and in combination were: 
probiotics / abdominal, probiotics / diarrhea / adult, symbiotic, probiotics / constipation, 
probiotics /abdominal pain, probiotics/bloating, probiotics/irritable bowel syndrome (IBS), and 
diarrhea/probiotics (Appendix A). 
The results of all the relevant databases were further refined with limits applied to exclude 
articles that were older than five years, non-English written articles and articles that included 
patients under the age of 18. In addition, articles that addressed in-patient populations were also 
excluded. Over half of these studies were dismissed due to poor study design, small sample size, 
insignificant results or inherent bias. The ten studies chosen for inclusion met the inclusion criteria 
and were relevant to all aspects of the PICOT question.  
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Evidence Synthesis 
 Despite the limitation of several studies included in this review, there is strong Level I and 
II evidence that probiotics have the potential to reduce IBS symptoms, antibiotic associated 
diarrhea, abdominal pain and bloating. 
This evidence suggests the strongest basis for the use of probiotics has been in the 
treatment of diarrhea caused by antibiotics and acute diarrheal episodes in adult subjects. A 
systematic review of the literature by Weichselbaum (2009), revealed seven large, randomized, 
controlled studies of which six were shown to have a significant reduction in severity and duration 
of diarrheal symptoms with mixed strains of probiotic use compared to placebo (Appendix B). In 
addition, a number of studies reviewed by Chatterjee et al. (2013) also showed a statistically 
significant reduction in abdominal pain, gas, and bloating that often accompany diarrheal episodes. 
These findings were further supported by a systematic review of the evidence by Szajewska and 
Kododziej (2015) who examined 21 randomized controlled trials and found 15 studies that showed 
a significant reduction in antibiotic associated diarrhea with the use of probiotics over placebo. In 
adult patients, diarrhea was reduced from 17% to 8% (RR .043, 95% CI: 0.3-0.6) with the use of 
the probiotic S.boulardii in various dosage amounts over placebo (Appendix B). A review of the 
evidence does suggest a significant reduction in antibiotic associated diarrhea duration and severity 
with the use of multiple probiotic strains with an adequate safety profile. 
 Parkes, Sanderson and Whelan (2010), reviewed 17 studies with adult patients diagnosed 
with irritable bowel syndrome and found a significant decrease in diarrhea, abdominal pain, gas 
and bloating symptoms with probiotic use in half the studies reviewed, but no change in 
constipation symptoms (Appendix B). A meta-analysis by Dimidi, Christodoulides, Konstantinos, 
Scott and Whelan (2014), evaluated the results of 14 randomized, placebo-controlled trials in adult 
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patients to determine the efficacy of probiotics for IBS symptoms (Appendix B).  Overall 
probiotics significantly reduced constipation measured by whole gut transit time by 12 hours (95% 
CI: -22.3, -2.5 hour, p<.01) and increased stool frequency by 1.3 bowel movements per week (95% 
CI: 0.07, 1.9 bowel movement/week, p<.01) compared to placebo in five studies (Appendix B). 
Although multiple strains of probiotics were used in the included studies, the probiotic strain 
Bifidobacterium lactis was used frequently and had the most significant effect on IBS symptoms.  
 This data was further supported by a randomized, placebo controlled trial conducted by 
Waller et al. (2011),  that showed a statistically significant 33% decrease in constipation, 27% 
reduction in abdominal pain and 32% reduction in bloating  over 14 day study period with the use 
of Bifidobacterium lactis over placebo in IBS patients (Appendix B). In addition, two randomized, 
placebo controlled trials conducted by Rogha, Esfahani and Zargarzadeh (2014) and Pineton de 
Chambrun et al. (2015) both showed a significant decrease in abdominal pain, bloating and 
diarrhea frequency with the use of probiotic over placebo, but failed to show a difference in 
constipation (Appendix B). Although several studies by Esken et al. (2015) showed a significant 
change in bowel movements with a decrease in constipation, this data remains unsupported by 
larger, randomized study results (Appendix B). Ford et al. (2014) reviewed 64 randomized 
controlled trials and found a majority that showed significant reduction in IBS symptoms 
(Appendix B).  In a majority of the IBS studies reviewed there appears to be a significant reduction 
in abdominal pain, gas, bloating and diarrhea with the use of probiotics, but little effect on 
constipation symptoms. 
Summary Recommendations 
The pathogenesis of functional GI disorders and IBS remains unclear and at least in part, 
appears multifactorial with numerous factors contributing to symptom severity. The possibility that 
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gut microbiota may have a role in IBS symptom relief is supported by sufficient Level I evidence 
that a number of probiotic strains are effective in reducing antibiotic associated diarrhea severity 
and duration in addition to abdominal pain, gas, and bloating associated with IBS (Appendix B). In 
addition, due to the lack of current treatment options for IBS patients and the adequate probiotic 
safety profile, their use could be a viable option for many patients.  Overall, the data illustrates the 
safety and effectiveness of probiotics use to reduce IBS symptoms: including abdominal pain, gas, 
bloating and diarrhea. 
Theoretical Framework 
Overall the research suggests probiotics may have a benefit in practice in specific patient 
populations. This recommendation is based on Stetler’s Model of Research utilization evidenced 
based practice model within the framework of the Health Belief Model (HBM) theoretical 
paradigm . This model allows for the unique patient /provider relationship based on evaluation of 
patient behavior, motivation and learning in an environment of caring and trust and incorporates 
phases of research utilization based on a foundation of critical thinking (White, K.M., Dudley-
Brown, S. & Terhaar, M., 2016) .  
The Stetler model is composed of five phases of research utilization: preparation, 
validation, comparison, implementation and evaluation (Stetler, C.B., et al., 1998). The evidence 
from internal data obtained from the outpatient GI clinic supports the current literature with regards 
to financial burden, prevalence and the need for further evaluation of potential effective therapies 
in functional GI disorders. The clinical expertise was further added to the decision making process 
in determining patient symptomology, diagnosis and available treatment modalities. This led to a 
comprehensive review of the available evidence which supports the use of probiotics as a valid 
treatment option for patients.  
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The Health Belief Model (HBM) allows for successful change based on an evaluation of 
patient behavior, motivation and learning in an environment of caring and trust and incorporates 
phases of behavior change based on a foundation of critical thinking and self-efficacy (Rosenstock, 
1966). The theory consists of four main constructs: susceptibility, seriousness of health condition, 
perceived benefits, and barriers (Rosenstock, 1966). Underlying the HBM theory is the concept of 
knowledge, which plays a key role in health motivation and self-efficacy. 
 Guided by Knowles Adult Learning theory, providing education that is patient centered, 
goal driven and involves a direct impact on their health can influence health outcomes (Knowles, 
G.J., 1998). According to Knowles’ Adult Learning Theory, adult learning provides the 
underpinnings of a patient’s willingness to change behaviors and utilize probiotics.  Adult learning 
provides the underpinnings of a patient’s willingness to change behaviors and utilize probiotics. 
    Methods 
The purpose of the project is to provide education to patients with chronic GI symptoms 
regarding probiotic use to manage symptoms and to evaluate if this education changes the patient’s 
willingness and self-efficacy to use probiotics as a means to manage their symptoms. 
Participants/Measures 
 Participants were adult patients with chronic functional GI symptoms seen at an outpatient 
GI clinic in Southwestern United States. Eligible participants included adult English speaking 
patients over the age of 18 with chronic GI symptoms (diarrhea, constipation, gas, bloating, IBS) 
seen in the outpatient setting. Arizona State University Institutional Review Board approval was 
obtained for study protocols prior to the start of project implementation and exempt status was 
granted. Participants were assured of strict confidentiality as all study material was anonymous and 
de-identified and kept in a locked office. Study participants were informed of all project 
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requirements and verbal consent was obtained from each patient prior to obtaining any project 
data. Collaboration with healthcare team which included physician, medical assistant and office 
staff regarding project evaluation, implementation and budget was effectively communicated by 
weekly meetings with the use of transformational leadership constructs. 
Participants were shown an educational video regarding the origins and benefits of using 
probiotics to manage chronic GI symptoms.  Knowledge of probiotics, self-efficacy and 
willingness to utilize probiotics was measured by asking participants to complete a modified 
Health Belief Model survey before and after viewing the video.  
The modified HBM survey included a total of 22 questions within six domains: perceived 
susceptibility, perceived seriousness, perceived benefits, perceived barriers, self-efficacy and 
knowledge and one question regarding willingness to use probiotics (Rosenstock, 1966). The scale 
utilized a five point Likert scale ranging from 1 (strongly disagree) to 5 (strongly agree). These 
items were chosen because they represent a wide range of contexts in which perceived self-efficacy 
has been measured reliably. The questionnaire was patterned after a valid prior survey with a 
reliability coefficient of .89 for the prior survey (Lee, Hwang, Hawkins, & Pingree, 2008). 
However, there is no a current survey that has been tested for validity and reliability that 
specifically addresses probiotic use and increased education. Therefore, survey language, content 
and construct validity were reviewed by Arizona State University professors. Demographic data 
including age and sex were also obtained.  
Statistical analysis/Results 
The Statistical Package for the Social sciences SPSS version 24.0 for Windows was used 
for analysis. Mean scale scores for the pre- and post-administration of each scale were evaluated 
for significant differences using the non-parametric Wilcoxon signed-rank test for hypothesis 
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testing of repeated measurements of a single sample. Non-parametric testing was chosen as it 
makes fewer assumptions about the distribution of responses, as the data was not a normal 
distribution. The sample included 64 females (86%) and 11 males (15%) that ranged in age from 
18 to 78 (M=40.3, SD=15.41). The results were significant with 65% of patients indicating they 
would try probiotics before educational video while 96% would try probiotics post video (CI 95%, 
p<.01), as shown in Table 1. Significant differences were also found in the results regarding 
improved self-efficacy, improved benefits , decreased barriers to probiotics use, as shown is Table 
2. The mean scale scores for all questions regarding self-efficacy were significantly higher post-
video compared to pre-video responses. The highest statistically significant improvement was 
found in the self-efficacy survey question: “I have been able to meet the goals I set for myself to 
improve my health” (Z=5.622, p<.01).  The mean scale scores for all questions regarding barriers 
to probiotic use were significantly reduced post- video compared to pre- video responses. The 
highest statistically significant decreased barrier found in the survey question was “Probiotics cost 
too much to use.”(Z-4.131, p<.01). The mean scale scores for all questions regarding benefits of 
probiotic use were also significantly higher post video compared to pre video. The highest 
significant improvement was found in the benefit survey question “I feel the benefits associated 
with probiotics outweigh the risks” (Z=5.713, p<.01). Categories concerning susceptibility and 
seriousness overall produced few significant results, as shown in Table 2. Baseline knowledge of 
probiotics were assessed using three true/false questions that showed significant improvement by 
binomial testing in knowledge of probiotics after viewing of  the video in correctly answering “Are 
probiotics good for you?” (91% pre-video to 100% post-video, CI 95%, p<.01) and “Do probiotics 
improve your immune system?” (91% pre-video to 100% post-video, CI 95%, p<.01) as shown in 
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Table 3. The question “Are you born with probiotics?” showed no significant improvement (CI 
95%, p.49). 
Discussion 
The evidence supports the use of probiotics in treating functional GI symptoms and 
suggests increased use of probiotics in practice would be beneficial for patient outcomes. The 
Health Belief Model hypothesizes that patients are more likely to change a behavior if they have 
adequate knowledge, recognize the benefits and risks associated with treatment and strong self-
efficacy (Rosenstock, 1966).This project has demonstrated that education of probiotics does 
significantly increase a patient’s self-efficacy regarding management of their symptoms, their 
perception of benefits of probiotics and decreases their barriers to using probiotics and increases 
patients’ willingness to use probiotics in the future.    
 Limitations of this evaluation included the ability to draw conclusions about the role that 
education itself played in the results by the fact that we did not have a comparison cohort of 
patients against which to compare survey results. In addition, small cohort size limited 
generalizability. While the project did demonstrate an increase in willingness to try probiotics, we 
cannot conclude that patients really did increase their utilization of probiotics, nor can we 
determine the effectiveness of the probiotics in management of these patients’ symptoms. 
The impact of the project influenced patients, provider practice and potential system 
effects. Patients gained increased education and improved self-efficacy and their willingness to use 
probiotics. For providers and the practice, increased education will be provided to patients at each 
office visit, and in the future further educational videos are being considered for other disease 
processes such as Crohn’s disease and ulcerative colitis. Health system effects include potential 
decreased healthcare costs and loss of productivity associated with functional GI disorders with the 
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increased use of probiotics. The project will be sustained in the future with the continued use of the 
educational video and is currently being translated for Spanish speaking patients. 
                                                            Conclusion 
The use of probiotics in clinical practice has the potential to reduce socioeconomic burden 
in regard to health care costs, productivity, and disability associated with functional GI disorders. 
Most importantly, with few treatment options available for patients suffering from IBS and 
functional GI disorders, the use of probiotics may alleviate patient suffering, pain, and disability 
and improve quality of life. The evidence, which supports current literature, suggests the use of 
educations increases patients self-efficacy and their willingness to use probiotics in the future. 
Increased education may be an effective method of increasing the number of patients who will use 
probiotics in the clinical setting, therefore improving functional GI symptoms, decreasing 
healthcare costs and loss of productivity. Based on these results, future studies could be considered 
to evaluate if patients actually started taking probiotics after increased education and whether 
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Appendix B Synthesis Table Summary of Evidence of Probiotic Use in Functional GI Disorders 
Author Date Type of Study Abdominal 
pain 
Sample Size Constipation Diarrhea  Gas/Bloating IBS symptoms 
Waller et al. (2011) RCT    100         
Chatterjee et al. 
(2013) 
RCT  396       
Rhoga et al. (2014) RCT    85           
Pineton de Chambrun 
et al. (2015) 
RCT    179             
Dimidi et al. (2014) Meta-
Analysis 
   14 Studies       





   164             
Parkes et al. (2010)a Meta-
Analysis 
 14 studies           
Ford et al. (2014) SR    64 RCT (6022 
patients) 
                          
Szajewska et al. 
(2015) 
SR  21 RCT (4078 
patients) 
          
Key:  Significant change in decrease of symptoms,  No significant change in symptoms,   Outcomes measured, RCT -Randomized 
Controlled Trial, SR-Systematic Review 
 
Table 1 Pateint willingness to try probiotics pre/post video 
  Frequency Percentage  2-tailed Signifiance 
Would try probiotics pre-video No  26 35  
 Yes 49 65 p=.01 
 Total 75 100  
Would try porbiotics post-video No 3 4  
 Yes 72 96 p=<.01 
 Total 75 100  
Note: CI(Confidenc Interval 95%), significance p<.05 
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Table 2 Survey questions pre/post video Wilcoxon signed-rank tests 







Probiotics cost too much to use Barriers to probiotic 
use 
   -4.131       
I do not know enough about probiotics to take them Barriers to probiotic 
use 
↑  3.416    01 
There are too many risks with taking probiotics Barriers to probiotic 
use 
   -3.575       
Taking probiotics is inconvenient for me Barriers to probiotic 
use 
   -2.491 p <.01 
I am confident I can have a positive effect on my health Self-efficacy ↑   3.934       
I have some definite goals to improve my health Self-efficacy ↑   4.732       
I have been able to meet the goals I set for myself to improve my health Self-efficacy ↑   5.622       
I am actively working to improve my health Self-efficacy ↑  4.869       
I feel that I am in control of how and what I learn about my health Self-efficacy ↑   4.337       
I feel I know a lot about probiotics and how they work Self-efficacy ↑  5.990       
Having chronic GI symptoms is a reason for taking probiotics Benefits ↑  4.828       
Taking probiotics will decrease my GI symptoms Benefits ↑  4.942       
I would consider taking probiotics Benefits ↑  4.660       
I feel the benefits associated with probiotics outweigh the risks Benefits ↑  5.713       
My GI symptoms disrupt me daily life Seriousness ↑  3.854       
My GI health is important to my well being Seriousness   -3.954      
I feel my GI symptoms are getting worse Seriousness   1.391      
I feel my GI symptoms will get worse in the future Susceptibility ↑  3.204       
I worry a lot about my future GI health Susceptibility   .4290       
I am aware of the possible benefits of probiotics in managing my GI 
symptoms 
Susceptibility ↑  3.991       
Note: ↓√Significant change in decrease of patient responses, ↔ No significant change in responses, ↑√ Significant improvement of 
patient responses, CI(Confidence Interval 95%), significance p<.05 
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Table 3 Education of probiotic pre/post video Binomial Testing 
 
Education Survey Binomial Test 
Survey Question Answer N Percentage Test Prop. Exact Sig. (2-tailed) 
Probiotics are good for you 
Prevideo 
 True 68 .91 .50 .      
 False 7 .09   
Total  75 1.00   
Probiotics are good for you 
Postvideo 
Group 1 True 75 1.00 .50 p<.01 
Total  75 1.00   
Probiotics Improve your 
immune system Prevideo 
Group 1 True 68 .91 .50 p<.01 
Group 2 False 7 .09   
Total  75 1.00   
Probiotics Improve your 
immune system Postvideo 
Group 1 True 74 .99 .50 p<.01 
Group 2 False 1 .01   
Total  75 1.00   
You are born with probiotics 
Prevideo 
Group 1 True 41 .55 .50 p..49 
Group 2 False 34 .45   
Total  75 1.00   
You are born with probiotics 
Postvideo 
Group 1 True 70 .93 .50 p<.01. 
Group 2 False 5 .07   
Total  75 1.00   
Note: CI(Confidence Interval 95%), significance p<.05 
 
 
 
